By vgreene, 14 April, 2020 Not currently available in the U.S. Used in Japan for tx of influenza. First approved drug in China for tx of COVID-19
By vgreene, 14 April, 2020 Proposed mechanism: interferes w/ host-regulated pathways involved in viral replication rather than a virus-targeted mechanism; broad-spectrum in vitro activity against various viruses, including coronaviruses
By vgreene, 14 April, 2020 Study considerations: non-comparative; selection and sampling bias; no prespecified endpoints; duration of f/u shorter than planned; significant proportion had mild dz; delayed tx initiation from sx onset
By vgreene, 14 April, 2020 68% of pts had improved O2 support category, 57% of pts w/ mech vent extubated, 13% of pts died; 60% experienced ADRs (23% serious); 23% of pts had elevated LFTs
By vgreene, 14 April, 2020 Prospective, observational study: 53 hospitalized pts (median age, 64y) w/ O2 sat